

NEWSLETTER

May-August 2025, Issue 21

Highlights

I . Business Progress

- Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth
- Viva Biotech Participates in the Establishment of a RMB 300 Million Venture Capital Fund, with Continued Focus on Early-Stage Biopharmaceutical Innovation
- Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery
- Peptide-Based Drug Design and AI-Driven Innovative Integration: Viva Biotech in Frontier Exploration
- Viva Biotech and Wepon Pharmaceutical reached a Strategic Cooperation on AI-Driven Innovation
- New Research Progress in Protein Structure: Viva Biotech Reveals the FANCM Helicase Domain Structure Published in the EMBO Journal
- Viva Biotech Continues to Drive Progress in Structural Biology: Contributes to a Novel PRMT5 Inhibitor Study in Journal of Medicinal Chemistry
- Viva Biotech Tackles Technical Barriers in Allosteric Inhibition, Boosting Potency by 25-Fold

II . Portfolio Companies' Project Progress

- NOVAtria® System of United InnoMed®: "Treatment+Monitoring" New Heart Failure Implants Appeared in ESC 2025
- ArthroSi Therapeutics Achieves Full Enrollment of the Second Pivotal Phase 3 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
- AceLink Therapeutics Completes 6-Month Primary Phase of AL01211 Clinical Study in Fabry Disease Patients
- VivaVision Biotech Secures Over RMB 100 Million Series D2+ Financing to Accelerate Ophthalmic Pipeline; VVN1901 Eye Drops Complete First Patient Dosing in Chinese Phase II Trial
- QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing, Accelerating Clinical Progress in Global Competition for Core Pipelines
- HAYA Therapeutics Raises \$65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
- AmacaThera and Merck Animal Health Announce Collaboration in Animal Health

Business Progress

WORLD-LEADING

ONE-STOP

PLATFORM

FOR INNOVATIVE

DRUG DISCOVERY

DEVELOPMENT

AND

MANUFACTURING

Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth

- On August 28, 2025, Viva Biotech Holdings Group (“Viva Biotech”, “the Group” or “the Company”, stock code: 1873.HK) announced that the Group's revenue amounted to RMB831.9 million, and the Group's gross profit of RMB339.4 million. The Group's gross profit margin was 40.8%, an increase of 6.3 percentage points from the corresponding period of last year, primarily attributable to the optimization and adjustment of Langhua's business structure, improved operational efficiency in CRO business, and contributions from new business segments. In the first half of 2025, the Group's net profit amounted to RMB148.6 million, representing a year-over-year increase of 3.1% compared to the net profit of RMB144.2 million for the corresponding period of last year; adjusted non-IFRS net profit improved from RMB168.2 million for the corresponding period of last year to an adjusted non-IFRS net profit of RMB183.5 million, representing a year-on-year increase of nearly 9.1%. This was mainly driven by the positive growth in both revenue from CRO business and adjusted non-IFRS net profit, as well as enhanced profitability resulting from the optimization of Langhua's business structure.
- Since the first half of 2025, benefiting from the recovery in global investment and financing sentiment last year and the booming BD transactions of innovative drugs domestically, the pipeline progression and R&D investments of drug development companies have been gradually rebounding. This has, to some extent, driven the restorative positive growth in the Group's CRO revenue. Additionally, the Group's CDMO business has seen a significant improvement in profitability due to the optimization and refinement of its product structure. With respect to the Group's CRO business, leveraging its global leadership in protein structure determination, it continued to enhance its technology platforms and expand its worldwide business development (BD) teams while prioritizing AI-driven empowerment of drug discovery platforms to sustain growth in both the number and scale of new projects through integrated wet-lab and dry-lab approaches. Regarding its CDMO business, active preparations were made for the implementation of new CDMO commercialization projects, with PPQ production already initiated within the Reporting Period. In addition, the Company has achieved significant improvement of profitability of its CMC business. Furthermore, the Group continued to benefit from investment returns and synergistic effects generated by its investment incubation initiatives. Overall, throughout the first half of 2025, the Group has consistently provided one-stop integrated services spanning from early-stage structure-based drug research and development to commercial drug production, achieving robust financial performance growth.

Viva Biotech Participates in the Establishment of a RMB 300 Million Venture Capital Fund, with Continued Focus on Early-Stage Biopharmaceutical Innovation

- On May 28, 2025, Hangzhou Viva Zongchen (a wholly-owned subsidiary of the Company) participated as a limited partner in the establishment and investment of an RMB-denominated fund, the total fund size is RMB 300 million, and is expected to contribute RMB25.0 million. The fund aims to seek investment with a focus on biopharmaceutical businesses to incubate and develop high quality pharmaceutical ventures, and further enable the Company to seek potential strategic partners and create synergies.

Business Progress

WORLD-LEADING

ONE-STOP

PLATFORM

FOR INNOVATIVE

DRUG DISCOVERY

DEVELOPMENT

AND

MANUFACTURING

Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery

- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery", unveiling the advanced and comprehensive AI-Driven Drug Discovery (AIDD) platform to the industry. During the event, Dr. Yue Qian, Executive Director of the AIDD/CADD Platform at Viva Biotech, delivered an in-depth overview of the unique strengths of the AIDD platform, its disruptive innovations across the drug discovery process, and its three core modules—V-Scepter, V-Orb, and V-Mantle. Through a series of case studies, Dr. Qian showcased how Viva's AIDD platform acts as a transformative "enchantment" for drug R&D, offering an intelligent, efficient, and integrated approach to accelerate the discovery of novel therapeutics.

Peptide-Based Drug Design and AI-driven Innovative Integration: Viva Biotech in Frontier Exploration

- As a witness and promoter of industry changes, Viva Biotech provides integrated research and development services from peptide screening to PCC. In July 2025, in its latest "Viva BioInsights" series live streaming "Deep Dialogue | Exploration Paths in Peptide-based Drug Design and AI-driven Innovation", the team deeply analyzed the technical secrets behind multiple breakthrough cases, and combined their own successful practices to bring exclusive innovative perspectives to industry colleagues. Viva Biotech has demonstrated the achievements in the integration of peptide-based drug design and AI-driven innovation, coping with the challenges of multi-target design, insufficient stability, and cyclic peptide synthesis. At the same time, it has achieved efficient screening and design, as well as conformational optimization and affinity enhancement. These cases fully demonstrate the deep empowerment of AI in various aspects of peptide-based drug design.

Viva Biotech and Wepon Pharmaceutical reached a Strategic Cooperation on AI-driven Innovation

- Recently, Viva Biotech (01873.HK), a leading one-stop drug R&D and production platform with AI empowerment, has reached a strategic cooperation with Wepon Pharmaceutical (002082.SZ), a comprehensive health company driven by dual-business development of medicine and medical devices. Based on their advantages in the fields of chemical medicine, traditional Chinese medicine and AI, the two sides will jointly cultivate new quality productivity and empower innovative drug research and development with AI. In addition, the two sides will also cooperate in the fields of innovative drug layout, AI industrial chain layout, AI medical talents training and global business development.

Business Progress

WORLD-LEADING
ONE-STOP
PLATFORM
FOR INNOVATIVE
DRUG DISCOVERY
DEVELOPMENT
AND
MANUFACTURING

New Research Progress in Protein Structure: Viva Biotech Reveals the FANCM Helicase Domain Structure Published in the EMBO Journal

- Recently, Viva Biotech contributed to the research published in The EMBO Journal, titled "Structural basis of Fanconi anemia pathway activation by FANCM". The study provides important new insights into the structure and functional mechanisms of FANCM. Dr. Dongming Qian, Vice President of Bioscience at Viva Biotech, and Dr. Yin Wu, Associate Director of Bioscience at Viva Biotech, played key roles in this study. Leveraging Viva Biotech's advanced platforms for protein production and structural analysis, they successfully resolved the high-resolution crystal structures of key FANCM domains in complex with DNA, providing crucial technical support and scientific evidence for the disclosure of this structural type.

Viva Biotech Continues to Drive Progress in Structural Biology: Contributes to a Novel PRMT5 Inhibitor Study in Journal of Medicinal Chemistry

- Recently, Viva Biotech contributed to an innovative research project published in the Journal of Medicinal Chemistry. The study, titled "Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion", detailed the evaluation of TNG462, a next-generation PRMT5 inhibitor. Viva Biotech leveraged its world-leading protein production and structural biology platform to provide strong technical support for this structure-based drug discovery effort.

Viva Biotech Tackles Technical Barriers in Allosteric Inhibition, Boosting Potency by 25-Fold

- In the challenging frontier of drug discovery, PCSK9, as a key target in cholesterol metabolism, has long been a major area of interest in cardiovascular drug R&D. Recently, a major breakthrough was achieved by a top global pharmaceutical company, with its small molecule PCSK9 inhibitor progressing successfully into Phase III clinical trials.
- Viva Biotech played a pivotal role in the early discovery and optimization of this compound by leveraging its proprietary and comprehensive technology platforms, along with the integrated efforts of multidisciplinary teams spanning structural biology, fragment screening, medicinal chemistry, and biophysics. The project progressed from a hit to a lead compound within one year and advanced to the preclinical candidate (PCC) stage within three years. The resulting PCC demonstrated picomolar (pM)-level binding affinity, underscoring the unique value of Viva Biotech's integrated drug discovery platform in tackling complex targets.

Portfolio Companies' Project Progress



NOVAtria® System of United InnoMed®: "Treatment+Monitoring" New Heart Failure Implants Appeared in ESC 2025

- From August 29th to September 1st, 2025, United InnoMed®, invested by Viva BioInnovator (VBI), attended the ESC Congress 2025 and World Congress of Cardiology. The results of its chronic animal experiment on NOVAtria® system (Feasibility of a novel implantable device to provide heart failure therapy and left atrial pressure monitoring in a chronic animal study) were successfully accepted by the Congress, and a presentation was delivered and shared in the Congress. This study validated the interatrial shunt patency and the accuracy of left atrial pressure measurement after using the device for 1-3 months, and showed the safety and feasibility of NOVAtria® system.
- NOVAtria® system, independently developed by United InnoMed®, integrates the functions of interatrial shunt therapy and left atrial pressure monitoring, which has great clinical significance in the management of chronic heart failure and has attracted extensive attention from experts attending the Congress.



ArthroSi Therapeutics Achieves Full Enrollment of the Second Pivotal Phase 3 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout

- Aug. 20, 2025 – ArthroSi Therapeutics, Inc., invested by Viva BioInnovator (VBI), a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, announced the completion of patient enrollment in its second pivotal global Phase 3 trial, REDUCE 1, evaluating pozdeutinurad (formerly AR882) for the reduction of sUA and tophi in gout and tophaceous gout patients.



AceLink Therapeutics Completes 6-Month Primary Phase of AL01211 Clinical Study in Fabry Disease Patients

- Aug. 18, 2025 – AceLink Therapeutics, invested and incubated by Viva BioInnovator (VBI), a clinical-stage biopharmaceutical company developing best-in-class substrate reduction therapies for lysosomal storage disorders, announced the successful completion of the 6-month primary treatment phase of its ongoing Phase 2 study of AL01211 (a novel oral GCS inhibitor) in treatment-naïve male patients with classic Fabry disease, with the drug demonstrating favorable safety and robust biomarker reduction.



VivaVision Biotech Secures Over RMB100 Million Series D2+ Financing to Accelerate Ophthalmic Pipeline; VVN1901 Eye Drops Complete First Patient Dosing in Chinese Phase II Trial

- July 21, 2025 -- VivaVision Biotech, invested by Viva BioInnovator (VBI), announced that it has completed the D2+ financing round delivery exceeding RMB100 million. The proceeds from the financing will be mainly used to accelerate the clinical progress in the middle and late stages of several core pipelines of the company, support the research and development of preclinical pipelines, and expand and upgrade the technological innovation platform, and continuously enhance R&D efficiency and capabilities.
- Previously, on July 16, VivaVision Biotech announced that the first patient had been successfully enrolled and dosed in its Phase II clinical trial in China for VVN1901 eye drops—an innovative drug independently developed by the company for the treatment of moderate to severe neurotrophic keratitis.

Portfolio Companies' Project Progress



QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing, Accelerating Clinical Progress in Global Competition for Core Pipelines

- June 5, 2025 -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio), invested by Viva BioInnovator (VBI), announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately USD 14 million) and was led exclusively by Efung Capital. This infusion of capital will be used to accelerate QureBio's clinical trials and advance its pipeline of novel antibody therapeutics. QureBio specializes in developing bispecific and multispecific antibody and protein therapeutics to address unmet medical needs in cancer, autoimmune diseases, and inflammatory disorders. The company has established a suite of proprietary technology platforms – including its I2T platform and its T-cell engager and NK-cell engager platforms – which form the foundation for its pipeline of novel drug candidates. Using these platforms, QureBio has built a robust pipeline of therapeutics aimed at previously intractable diseases.



HAYA Therapeutics Raises \$65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases

- May 8, 2025 – HAYA Therapeutics, invested by Viva BioInnovator (VBI), a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has raised \$65 million in Series A funding. The financing will accelerate the clinical development of HAYA's lead long non-coding RNA (lncRNA) targeting candidate HTX-001 in heart failure and the continued expansion of its RNA-guided regulatory genome pipeline development engine. This investment emphasizes investor confidence in HAYA's groundbreaking science and positions the company to deliver on its mission of bringing disease-modifying, precision medicines faster and more efficiently to patients.



AmacaThera and Merck Animal Health Announce Collaboration in Animal Health

- May 1, 2025 -- AmacaThera, invested by Viva BioInnovator (VBI), a clinical-stage biotechnology company specializing in drug delivery, announced it has signed a binding evaluation and option agreement with Merck Animal Health to develop long-acting formulations, for use in animal health. Built upon AmacaThera's unique hydrogel platform technology, AmacaGel™, products developed by AmacaThera are designed to enhance the sustained delivery of therapeutic agents with a single injection, potentially revolutionizing animal care and welfare in veterinary medicine. Both companies anticipate a fruitful collaboration, with the shared goal of advancing innovative animal health solutions, thereby enabling veterinarians to provide better care.



Listing Date
2019.05.09

Price (2025.9.26)
HKD 2.41

52 WK Range
HKD 0.77 – 2.93

Market Cap (2025.9.26)
HKD 5.130 Billion

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of June 30, 2025, Viva Biotech had cumulatively provided drug R&D and manufacturing services to 2,574 biotech and pharmaceutical clients around the world. We have invested and incubated 93 biotech start-ups in total. In the future, the company will continue to strengthen its technological barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com
For further information, please contact: Tel: +86(0)21-6089 3288
Email: ir@vivabiotech.com